Efficacy and Safety of Doravirine/Islatravir (100 mg/0.25 mg) Once Daily as Initial HIV-1 Therapy by Demographic Subgroups: Week 48 Results From a Randomized, Active-Controlled Phase 3 Study

Conference Reports for NATAP

13th IAS Conference on HIV Science
IAS 2026
July 26-31 Rio, Brazil


Efficacy and Safety of Doravirine/Islatravir (100 mg/0.25 mg) Once Daily as Initial HIV-1 Therapy by Demographic Subgroups: Week 48 Results From a Randomized, Active-Controlled Phase 3 Study

	IAS 2026 Rio, Brazil Brenda Crabtree Ramírez1,*